$ABT

Morrone Louis H. sold $643K of ABT

Morrone Louis H. (EXECUTIVE VICE PRESIDENT) sold 5,850 shares of ABBOTT LABORATORIES (ABT) at $109.83 ($0.64M total) on 2026-08-11.

Original reporting
SEC EDGAR · Morrone Louis H.
Published Aug 13, 2026, 9:14 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 13, 2026, 9:45 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ABT
Neutral
medium confidence
Mentioned
$ABT
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ABTNeutralLow
01

Why it matters

The newest fact is the specific open-market sale details (shares, price, total value, and post-transaction holdings).

02

Market read

Traders may briefly watch for sentiment effects from insider selling, but there is no accompanying fundamental catalyst in the text.

03

What to watch

Insider sales can be driven by diversification, taxes, or pre-scheduled personal liquidity needs; the article provides no stated reason for the sale.

Relevance 5/10Novelty 3/10Timing: filed after-hours on 2026-08-13, covering a sale dated 2026-08-11

Background

The article is an SEC Form 4 insider transaction disclosure for Abbott Laboratories (ABT).

Company-level read

Ticker impact

$ABTNeutralMedium confidence
Context

Abbott Laboratories Form 4 shows EVP Morrone Louis H. sold 5,850 shares at $109.83 on 2026-08-11 for about $642.5K.

Expected impact

Low likelihood of a sustained price move; any near-term impact would be sentiment-driven and typically fades.

Evidence & confidence

The filing discloses transaction size, price, and post-sale holdings, but provides no new company-specific operational, financial, or regulatory information.

Market effects

No clear sector read-through; insider sales are common and not a sector catalyst by themselves.

None indicated.

None indicated.

Counterpoint

Because the filing states no pre-arranged 10b5-1 plan, some traders may interpret the sale as higher near-term risk, even though insider sales are often non-informational.

Key entities

  • Abbott Laboratories

    Subject of the Form 4 insider transaction disclosure.

  • Morrone Louis H.

    Executive Vice President who sold shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ABTMed

Why is Abbott Laboratories stock gaining today?

Abbott Laboratories shares rose about 1.2% in morning trading after the company announced a multi-year collaboration with Google Health. Abbott’s Lingo continuous glucose monitor data will be integrated into the Google Health app, with personalized coaching via Google Health Coach and a large real-world metabolic study. The move was driven by company-specific news amid a flat U.S. market.

$GHMedAI 8/10

New blood test to detect colon cancer clears FDA approval

The FDA approved Freenome’s SimpleScreen blood test for colorectal cancer screening in adults aged 45+ at average risk. In a study of 48,000+ people, it detected about 80% of colorectal cancers and correctly tested negative in about 90% without cancer or advanced precancer. It is expected to launch this fall with Abbott. Guardant Health’s Shield was approved in 2024.